Artal Group’s Aldeyra Therapeutics ALDX Stock Holding History

Artal Group’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-431,894	Closed	-$4.89M	–	148
2021 Q2	$4.89M	Buy	+431,894	New	+$5.19M	0.1%	120

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Artal Group's ALDX Position: Q3 2021 in Review

Artal Group sold out of Aldeyra Therapeutics (ALDX) in Q3 2021, closing a stake of 431,894 shares — an estimated $4.89M sold.

Artal Group first reported a position in ALDX in Q2 2021 and held it in 1 quarter. The position peaked at $4.89M in Q2 2021. 117 funds tracked by Wall St. Rank hold ALDX as of Q3 2021.

Artal Group reported no remaining Aldeyra Therapeutics position as of Q3 2021 after selling out during the quarter.
Artal Group sold 431,894 Aldeyra Therapeutics shares in Q3 2021, an estimated $4.89M.
Artal Group first reported a position in Aldeyra Therapeutics in Q2 2021 and held it in 1 quarter.
Artal Group's Aldeyra Therapeutics position peaked at $4.89M in Q2 2021.
117 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2021.

Based on Artal Group's 13F filing for Q3 2021, filed 12 Nov 2021.